Anti-Aging Firm Unity Stumbles At First Major Hurdle
Hit By Lead Drug Failure In OA
Unity is set to drop its lead product based on its senescent cell science as it fails in a Phase II study in osteoarthritis of the knee. Focus switches to ophthalmic product.
You may also be interested in...
Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.
The financing, which brings the total raised by Juvenescence to $165m, comes as longevity R&D programs supported by the company move towards human testing.
The firm’s potential new therapy for the negative symptoms of schizophrenia is now in the hands of the US Food and Drug Administration – some have concerns over whether the supporting data will be enough.